Infinity Pharmaceuticals Inc (NASDAQ: INFI) reported an IPI-549 late-breaking presentation at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
The company, based in Cambridge, Mass., reported Thursday that an abstract describing new data for IPI-549, an orally-administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), has been selected as a late-breaking presentation during an oral session at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in National Harbor, Md., scheduled to take place in mid-November.
Additionally, a clinical trials in progress poster will also be presented on the Phase 1/1b clinical study which is ongoing to explore the safety and activity of IPI-549 both as a monotherapy and in combination with Opdivo® (nivolumab), a PD-1 immune checkpoint inhibitor, in patients with advanced solid tumors. IPI-549 is believed to be the only PI3K-gamma inhibitor in clinical development.
A Phase 1 study of IPI-549 in patients with advanced solid tumors is ongoing to evaluate the safety, tolerability, activity, pharmacokinetics and pharmacodynamics of IPI-549 as a monotherapy and in combination with Opdivo in approximately 200 patients with advanced solid tumors.The four-part study includes monotherapy and combination dose-escalation components, in addition to monotherapy expansion and combination expansion components. Patient enrollment is complete in monotherapy dose-escalation, and monotherapy expansion is ongoing. Combination dose-escalation is also ongoing, and combination expansion is expected to begin as the year draws to a close.
Infinity stock nearly doubled in the last hour of trading on Thursday, triumphing $1.55, or 92.8%, to $3.22.
Related Stories
